Meet Neuland at CPHI India 2026 | Hall 2, Booth 2D38 | Yashobhoomi Convention Centre, New Delhi | 24-26 November 2026 Schedule a Meeting
How Neuland developed an innovative synthesis strategy for a complex 25-amino-acid peptide, overcoming insolubility and impurity challenges to support clinical development
In this case study, discover how Neuland partnered with a European biotechnology company developing an osteoporosis therapy to design an entirely new manufacturing process for a 25AA peptide API. Despite having access only to the peptide sequence, Neuland successfully developed a scalable SPPS-based synthesis route, minimized impurity formation, resolved purification challenges, and delivered GMP material for clinical development.